See more : Nextdoor Holdings, Inc. (KVSB) Income Statement Analysis – Financial Results
Complete financial analysis of Galmed Pharmaceuticals Ltd. (GLMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galmed Pharmaceuticals Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Rugvista Group AB (publ) (RUG.ST) Income Statement Analysis – Financial Results
- HEXPOL AB (publ) (HPOL-B.ST) Income Statement Analysis – Financial Results
- JPMorgan Chase & Co. (JPM-PL) Income Statement Analysis – Financial Results
- IRONWOOD EDUCATION LIMITED (IRONWOOD.BO) Income Statement Analysis – Financial Results
- BHG Group AB (publ) (BHG.ST) Income Statement Analysis – Financial Results
Galmed Pharmaceuticals Ltd. (GLMD)
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.04M | 1.09M | 467.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 31.00K | 35.00K | 42.00K | 39.00K | 35.00K | 0.00 | 0.00 | 0.00 | 50.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -31.00K | -35.00K | -42.00K | -39.00K | -35.00K | 2.04M | 1.09M | 467.00K | -50.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.57M | 13.00M | 27.22M | 26.08M | 18.18M | 8.31M | 9.65M | 14.27M | 7.63M | 6.66M | 7.21M | 2.44M |
| General & Administrative | 3.72M | 4.66M | 5.66M | 4.13M | 4.20M | 4.44M | 3.80M | 3.08M | 3.25M | 2.48M | 7.36M | 694.00K |
| Selling & Marketing | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.92M | 4.66M | 5.66M | 4.13M | 4.20M | 4.44M | 3.80M | 3.08M | 3.25M | 2.48M | 7.36M | 694.00K |
| Other Expenses | -14.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.00K | 0.00 |
| Operating Expenses | -7.49M | 17.65M | 32.88M | 30.21M | 22.38M | 12.75M | 13.45M | 17.35M | 10.88M | 9.14M | 14.56M | 3.14M |
| Cost & Expenses | -7.49M | 17.65M | 32.88M | 30.21M | 22.38M | 12.75M | 13.45M | 17.35M | 10.88M | 9.14M | 14.56M | 3.14M |
| Interest Income | 375.00K | 297.00K | 562.00K | 1.19M | 1.92M | 959.00K | 65.00K | 35.00K | 253.00K | 40.00K | 0.00 | 6.00 |
| Interest Expense | 11.00K | 215.00K | 43.00K | 31.00K | 33.00K | 42.00K | 49.00K | 67.00K | 0.00 | 0.00 | 34.00K | 0.00 |
| Depreciation & Amortization | 31.00K | 35.00K | 42.00K | 39.00K | 35.00K | 387.00K | 239.00K | 169.00K | 50.00K | 9.00K | 4.00K | 5.00K |
| EBITDA | -6.87M | -17.62M | -32.84M | -30.17M | -22.34M | -10.33M | -12.13M | -16.71M | -10.83M | -9.13M | -14.57M | -3.13K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -507.61% | -1,117.51% | -3,578.80% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 7.49M | -17.65M | -32.88M | -30.21M | -22.38M | -10.72M | -12.36M | -16.88M | -10.88M | -9.14M | -14.57M | -3.14M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -525.76% | -1,139.54% | -3,614.99% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -14.40M | -215.00K | 414.00K | 1.44M | 1.92M | 934.00K | 65.00K | 35.00K | 253.00K | 40.00K | -2.92M | -6.00K |
| Income Before Tax | -6.91M | -17.87M | -32.47M | -28.77M | -20.46M | -9.78M | -12.30M | -16.85M | -10.62M | -9.10M | -17.48M | -3.14M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -479.93% | -1,133.55% | -3,607.49% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 705.00K | -519.00K | -1.16M | -1.92M | 75.00K | 12.36M | 106.00K | 21.24M | 1.00K | 1.00K | 6.00K |
| Net Income | -6.91M | -18.57M | -31.95M | -27.61M | -18.54M | -9.86M | -12.30M | -16.95M | -10.62M | -9.10M | -17.49M | -3.15M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -483.61% | -1,133.55% | -3,630.19% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -30.05 | -11.08 | -19.48 | -19.46 | -13.17 | -8.15 | -14.77 | -22.36 | -14.35 | -13.23 | -24.57 | -9.32 |
| EPS Diluted | -29.95 | -11.08 | -19.48 | -19.46 | -13.17 | -8.15 | -14.77 | -22.36 | -14.35 | -13.23 | -24.57 | -9.32 |
| Weighted Avg Shares Out | 230.00K | 1.68M | 1.64M | 1.42M | 1.41M | 1.21M | 832.49K | 758.31K | 740.03K | 688.25K | 711.66K | 337.96K |
| Weighted Avg Shares Out (Dil) | 230.79K | 1.68M | 1.64M | 1.42M | 1.41M | 1.21M | 832.49K | 758.31K | 740.03K | 688.25K | 711.66K | 337.96K |
FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2021 Results - Earnings Call Transcript
Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results
Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines
Galmed Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Business Update on Thursday May 13
Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study
GLMD Stock Price Increased 14.62%: Why It Happened
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2020 Results - Earnings Call Transcript
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results
Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER
Source: https://incomestatements.info
Category: Stock Reports